MindMed Expects Results For Anxiety, ADHD Trials By Late 2023
It seems it is business as usual for Mind Medicine, aka MindMed, (NASDAQ: MNMD) as the firm gave updates on
Read moreIt seems it is business as usual for Mind Medicine, aka MindMed, (NASDAQ: MNMD) as the firm gave updates on
Read moreFCM MM Holdings, one of Mind Medicine’s (NEO: MMED) shareholders with a 6.1% stake, has formally filed a complaint with
Read moreThis past week Mind Medicine Inc. (NEO: MMED) announced that they would be doing a public offering of 7,058,823 units
Read moreMind Medicine (NEO: MMED) has elected to destroy shareholder value in a major way this morning, pricing yet another financing
Read moreMind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Tuesday that the first patient has been dosed
Read moreMind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday that the previously released positive topline data
Read moreMind Medicine (NEO: MMED) might be slightly more volatile over the next few sessions. The psychedelic firm late on Friday
Read moreMind Medicine (NEO: MMED) has officially seen patient trials under a Phase 2b study get underway as it looks to
Read moreMind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday its financial results for Q2 2022. The
Read moreAn activist shareholder battle might be brewing at Mind Medicine (NEO: MMED). This morning, co-founder of the company Dr Scott
Read more